Total Assets$XTALPI(02228.HK) Today, XtalPi (2228.HK), a global leading platform company driven by artificial intelligence (AI) and robotic automation experimental technology for R&D innovation, announced a collaboration with global pioneer in in vivo gene editing and base editing technology, Yaotang (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Yaotang Bio"), for innovative AI-driven messenger RNA (mRNA) drug R&D. The two parties will focus on the fields of mRNA drugs and CAR-T therapy, jointly building an AI-driven closed-loop screening platform for mRNA wet and dry lab experiments. By combining XtalPi's cutting-edge AI modeling capabilities with Yaotang Bio's extensive experience in mRNA drugs and gene editing, they aim to reshape the paradigm of mRNA drug development, accelerate the advent of breakthrough therapies, and benefit patients worldwide.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
